Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression

Xiaoxu Huang1,2†, Zheng Li†, Qiang Zhang1†, Weizhi Wang1†, Bowen Li1, Lu Wang1, Zhipeng Xu1, Ailiang Zeng3, Xing Zhang1, Xuan Zhang1, Zhongyuan He1, Qiang Li1, Guangli Sun1, Sen Wang1, Qing Li1, Linjun Wang1, Lu Zhang1, Hao Xu1 and Zekuan Xu1*†

Abstract

Background: Cisplatin (CDDP) treatment is one of the most predominant chemotherapeutic strategies for patients with gastric cancer (GC). A better understanding of the mechanisms of CDDP resistance can greatly improve therapeutic efficacy in patients with GC. Circular RNAs (circRNAs) are a class of noncoding RNAs whose functions are related to the pathogenesis of cancer, but in CDDP resistance of GC remains unknown.

Methods: circAKT3 (hsa_circ_0000199, a circRNA originating from exons 8, 9, 10, and 11 of the AKT3 gene) was identified by RNA sequencing and verified by quantitative reverse transcription PCR. The role of circAKT3 in CDDP resistance in GC was assessed both in vitro and in vivo. Luciferase reporter assay, biotin-coupled RNA pull-down and fluorescence in situ hybridization (FISH) were conducted to evaluate the interaction between circAKT3 and miR-198. Functional experiments were measured by western blotting, a cytotoxicity assay, clonogenic assay and flow cytometry.

Results: The expression of circAKT3 was higher in CDDP-resistant GC tissues and cells than in CDDP-sensitive samples. The upregulation of circAKT3 in GC patients receiving CDDP therapy was significantly associated with aggressive characteristics and was an independent risk factor for disease-free survival (DFS). Our data indicated that circAKT3 promotes DNA damage repair and inhibits the apoptosis of GC cells in vivo and in vitro. Mechanistically, we verified that circAKT3 could promote PIK3R1 expression by sponging miR-198.

Conclusions: circAKT3 plays an important role in the resistance of GC to CDDP. Thus, our results highlight the potential of circAKT3 as a therapeutic target for GC patients receiving CDDP therapy.

Keywords: Cisplatin resistance, Gastric cancer, circAKT3, Circular RNA, miR-198, PIK3R1

Background

Gastric cancer (GC) is the most common malignant tumor of the digestive tract in East Asia and the third leading cause of cancer-related death worldwide [1, 2]. At present, the main treatments for advanced GC are systemic chemotherapy and palliative surgery, but the overall median survival after treatment is only 8 to 11 months [3]. In patients with histologically confirmed advanced GC and who are chemotherapy-naïve, cisplatin (CDDP) and fluorouracil-based chemotherapies were deemed as first-line treatments [4]. However, patients always acquired drug resistance after several cycles of CDDP-based treatment. Thus, chemotherapy resistance has limited overall clinical efficacy in patients [5, 6]. To improve GC patient survival, illuminating the molecular mechanism underlying CDDP resistance in GC is essential.

The cytotoxicity of CDDP is mediated by its interaction with DNA to form DNA adducts. Intracellular CDDP primarily binds to nuclear DNA with high affinity and can physically interact with mitochondrial DNA
miR-198 that suppresses PIK3R1 expression via activation of caspase-3 and prevents the activation of caspase-3 and the inhibition of apoptosis [12].

Circular RNAs (circRNAs), a category of noncoding RNAs (ncRNAs), play a crucial role in the process of transcriptional and posttranscriptional gene expression [13]. Recently, circRNAs were found to function as competitive endogenous RNAs (ceRNAs) to sponge microRNAs (miRNAs) and then suppress their functions, indicating a novel mechanism for regulating miRNA activity and providing a promising mode of action for circRNAs. As miRNAs regulate a series of biological processes, circRNA sponge activity will affect these biological behaviors as well [13]. miRNAs are a large class of short (~22 nt) ncRNAs that posttranscriptionally regulate gene expression through direct base pairing to target sites within mRNAs. circRNAs can affect miRNA activities by competing for miRNA-binding sites [13]. However, the function of circRNAs as miRNA sponges has not been clearly elucidated in GC resistance to CDDP.

To investigate the potential roles of circRNAs in the regulation of CDDP resistance in GC, we performed RNA sequencing (RNA-Seq) and verified thousands of distinct circRNAs in CDDP-sensitive and CDDP-resistant GC cells from humans. Through functional gain and loss experiments, we further observed that hsa_circ_0000199, which originates from exons 8, 9, 10, and 11 of the AKT3 gene and is termed circAKT3, was significantly upregulated in both CDDP-resistant GC tissues and in the regulation of chemotherapy resistance of cancer cells [10, 11]. Activated PI3K/AKT signaling promotes the phosphorylation of caspase-3 and prevents the activation of caspase-3 and the inhibition of apoptosis [12].

Cell culture

The CDDP-resistant cell lines SGC7901 and BGC823 as well as their CDDP-resistant strains (SGC7901CDDP and BGC823CDDP, respectively) were maintained in RPMI 1640 medium (Wisent, Shanghai, China) supplemented with 10% fetal bovine serum (FBS) (Wisent, Biocenter, China) (Additional file 2: Figure S1A). 293 T cells were cultured in DMEM with high glucose (Gibco-BRL, Carlsbad, CA, USA) supplemented with 10% FBS, 293 T, SGC7901CDDP, BGC823 and SGC7901 cells were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences, and BGC823CDDP cells were established as previously described [15].

miRNA targets prediction of circAKT3

To predict the miRNA-binding sites of circAKT3, we used the bioinformatic databases miRanda, PITA and RNAhybrid. Filtering restrictions were as follows: (1) total score ≥ 140, total energy < 17 kcal/mol; (2) combined interaction energy (ΔΔG) < 10; and (3) minimum free energy (MFE) ≤ 20 kcal/mol. Detailed information is listed in Additional 3: Dataset S1.

RNA preparation, treatment with RNase R, and PCR

Total RNA was extracted from GC cells or tissues using TRIzol Reagent (Invitrogen, 15,596,018). RNase R treatment was carried out for 15 min at 37 °C using 3 U/mg RNase R (Epicenter). For Quantitative real-time PCR (RT-PCR), 500 ng of treated RNA was directly reverse transcribed using Prime Script RT Master Mix (Takara, Japan) and either random or oligo(dT) primers. Reverse transcription of mRNA was performed using a New Poly(A) Tailing Kit (ThermoFisher Scientific, China). mRNA was reverse transcribed into cDNA with a PrimeScript RT Master Mix Kit (Takara, RR036A, Japan). cDNA was amplified using Universal SYBR Green Master Mix (4,913,914,001, Roche, Shanghai, China). The CT value was measured during the exponential growth phase. Relative gene expression levels were determined...
Fig. 1 (See legend on next page.)
using the 2-ΔΔCT method. The primers used are listed in Additional file 1: Table S2.

**Isolation of nuclear and cytoplasmic fractions**

SGC7901CDDP and BGC823CDDP cells were lysed on ice for 10 min in 0.3% NP-40/NIB-250 buffer (15 mM Tris–HCl (pH 7.5), 60 mM KCl, 15 mM NaCl, 5 mM MgCl₂, 1 mM CaCl₂ and 250 mM sucrose) supplemented with protease inhibitors. After centrifugation at 600 × g for 5 min at 4 °C, the resultant supernatant was collected as the cytoplasmic fraction and mixed with an equal volume of TRIsure reagent. After the pellet was washed with NIB-250, the nuclei were lysed in TRIsure reagent.

**Fig. 1**

circAKT3 expression is increased in CDDP-resistant GC cells and tissues. 

a. Validated expression of 10 circRNAs in the tissues from 44 GC patients using RT-qPCR. 

b. Expression levels of circAKT3 in CDDP-resistant and their matched sensitive parental cell lines (SGC7901CDDP, BGC823CDDP, SGC7901 and BGC823) normalized to GAPDH expression. 

c. The existence of circAKT3 was validated by Sanger sequencing. The red arrow shows the "head-to-tail" splicing sites of circAKT3. 

d. The existence of circAKT3 was validated in SGC7901CDDP and BGC823CDDP cell lines by RT-PCR. Divergent primers amplified circAKT3 in cDNA but not in genomic DNA (gDNA). GAPDH served as a negative control. 

e. RNA from SGC7901CDDP and BGC823CDDP cells was treated with or without RNase R for RT-qPCR. The relative levels of circAKT3 and AKT3 mRNA were normalized to the values measured in the mock-treated cells. 

f. Levels of small nucleolar RNA (U6, as a positive control for the nuclear fraction), GAPDH (positive control for cytoplasmic fraction), AKT3 mRNA and circRNAs from the nuclear and cytoplasmic fractions of SGC7901CDDP cells. 

g. RNA stability of circular and linear transcripts of AKT3 and of 18S rRNA in SGC7901CDDP cells. 

h. Representative images of RNA FISH of circAKT3 expression in SGC7901CDDP cells, which show that circAKT3 is predominantly localized to the cytoplasm. Nuclei were stained with DAPI. Scale bar, 10 μm. The results are presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001

**Fig. 2**

The circAKT3 expression level is correlated with poor prognosis in GC patients receiving CDDP therapy. 

a. Expression levels of circAKT3 in tissue samples of 105 GC patients (CDDP-resistant and CDDP-sensitive groups) normalized to GAPDH expression. 

b. Kaplan-Meier survival curves of DFS for patients with high (n = 53) or low (n = 52) circAKT3 expression. The median circAKT3 expression value was used as the cutoff. 

c. ROC curves of circAKT3. 

d. Multivariate analyses of hazard ratios for DFS. The results are presented as the mean ± SEM.
Vector construction

The method for overexpressing circRNAs was reported previously [16]. For the construction of circAKT3 overexpression plasmids, human circAKT3 cDNA was amplified using PrimerSTAR Max DNA Polymerase Mix (Takara, RR036A, Japan) and inserted into the pCD5-ciR vector (Greenseed Biotech Co, Guangzhou, China). The pCD5-ciR vector contains a front circular frame and a back circular frame. Transfection was carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. The luciferase reporter containing the circAKT3 sequence in the 3′-UTR was constructed by subcloning the circAKT3 fragment into the region directly downstream of a cytomegalovirus promoter-driven firefly luciferase (FL) cassette in a pCDNA3.0 vector. Mutations of each miRNA-binding site in the circAKT3 sequence were created using a Mut Express II Fast Mutagenesis Kit (Vazyme, Nanjing, China). The mutations were introduced in both the circAKT3-expressing vector and the luciferase reporter containing the circAKT3 sequence.

Oligonucleotide transfection

siRNA and miRNA mimics and inhibitors were synthesized by GenePharma (Shanghai, China). The sequences used are listed in Additional file 1: Tables S3 and S4. Transfection was carried out using Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer’s instructions.

RNA pull-down

A pull-down assay was performed as described previously [17, 18]. The biotin-labeled circAKT3 probe was synthesized by RiboBio (Guangzhou, China). In brief, 1 × 10⁷ circAKT3-overexpressing GC cells were harvested, lysed, and sonicated. The circAKT3 or oligo probe was incubated with streptavidin-coupled Dynabeads (Invitrogen) at 30°C overnight to generate probe-bound Dynabeads. After the treated beads were washed with wash buffer, the RNA complexes bound to the beads were eluted and disrupted with lysis buffer and proteinase K prior to RT-PCR or RT-qPCR. Biotinylated probes sequences used in this study (see Additional file 1: Table S5).

Luciferase reporter assay

293 T, SGC7901CDDP and BGC823CDDP cells were seeded in 24-well plates and cotransfected with corresponding plasmids and miRNA mimics in triplicate. At 48 h after transfection, luciferase reporter assays were conducted using a dual-luciferase reporter assay system (Promega, Madison, WI) according to the manufacturer’s instructions. Relative luciferase activity was normalized to Renilla luciferase activity.

Fluorescence in situ hybridization (FISH)

The double FISH assay was performed in SGC7901CDDP cells and GC tissues as previously described [16, 19]. Biotin-labeled probes specific to circAKT3 and Dig-labeled locked nucleic acid miR-198 probes were used in the hybridization (Exiqon, Vedbaek, Denmark). The sequences are listed in Additional file 1: Table S6, FISH probes sequences used in this study. The signals of the biotin-labeled probes were detected using Cy5-conjugated streptavidin (Life Technologies), and the signals of the Dig-labeled miR-198 probes were detected using a tyramide-conjugated Alexa 488 fluorochrome TSA kit. Nuclei were counterstained with 4,6-diamidino-2-phenylindole. Images were acquired on a Leica TCS SP2 AOBS confocal microscope (Leica Microsystems, Mannheim, Germany). CircAKT3 and miR-198 expression levels were evaluated by the proportions and intensities of the positive cells detected within 5 fields of view on every slide (400-fold magnification). Proportion scores were assigned as follows: < 10% = 0, 10–25% = 1, 26–50% = 2, 51–75% = 3 and > 75% = 4. Intensity scores

Table 1 Correlation of relative circAKT3 expression with the clinicopathological characteristics of 105 patients accepted cisplatin-based chemotherapy with gastric cancer

| Characteristics         | Number | No. of patients | P value |
|-------------------------|--------|----------------|---------|
|                         | circAKT3high | circAKT3low |         |
| Age(y)                  |         |               |         |
| < 60                    | 62      | 34            | 28      | 0.283   |
| ≥ 60                    | 43      | 19            | 24      |         |
| Gender                  |         |               |         |
| Male                    | 80      | 37            | 43      | 0.121   |
| Female                  | 25      | 16            | 9       |         |
| Tumor size(cm)          |         |               |         |
| < 3.5                   | 56      | 21            | 35      | 0.004** |
| ≥ 3.5                   | 49      | 32            | 17      |         |
| Histological grade      |         |               |         |
| Well-moderately          | 33      | 11            | 22      | 0.017*  |
| Poorly-signet           | 72      | 42            | 30      |         |
| Clinical stage           |         |               |         |
| II                      | 39      | 13            | 26      | 0.007** |
| III                     | 66      | 40            | 26      |         |
| T classification         |         |               |         |
| T1-T2                   | 31      | 9             | 22      | 0.004** |
| T3-T4                   | 74      | 44            | 30      |         |
| N classification         |         |               |         |
| N0                      | 14      | 5             | 9       | 0.232   |
| N1-N3                   | 91      | 48            | 43      |         |
| Cisplatin chemosensitivity |       |               |         |
| Sensitive               | 92      | 41            | 51      | 0.001** |
| Resistant               | 13      | 12            | 1       |         |

Table 1 Correlation of relative circAKT3 expression with the clinicopathological characteristics of 105 patients accepted cisplatin-based chemotherapy with gastric cancer

Huang et al. Molecular Cancer (2019) 18:71
Fig. 3 (See legend on next page.)
were assigned as follows: 0 = no staining, 1 = weak, 2 = moderate, 3 = strong and 4 = significantly strong.

**Western blot analysis**

For western blot analysis, cells were extracted using a protein extraction kit (Key Gene, KG9100). Lipid proteins were added into 8, 10, 12% or 15% gels, subjected to 120 V to promote migration, and then transferred onto nitrocellulose membranes. The membranes were blocked with 5% BSA in TBST buffer and incubated with specific primary antibodies at 4 °C overnight. The next day, membranes were washed 3 times for 15 min in TBST and incubated with secondary antibodies for 2 h at room temperature. HRP substrate (WBKLO100, Millipore, USA) was used to detect the protein bands (Molecular Imager, ChemiDoc XR+ı, BIO-RAD, USA), and the band intensities were quantified using Image-Pro Plus software (Mediacy, USA). Detailed information of antibody used in this study (see Additional file 1: Table S7).

**Cytotoxicity assay**

The cytotoxicity assay was performed as previously described [15]. Cell viability was measured using Cell Counting Kit-8(CCK8)following the manufacturer's directions (Dojindo, Kumamoto, Japan).

**Clonogenic assay**

A clonogenic assay was performed as previously described [15]. At 48 h after transfection, BGC823CDDP, SGC7901CDDP, BG823 and SGC7901 cells were cultured with CDDP at the indicated concentrations for 3 h. Then, the cells were harvested, seeded into six-well plates (500 cells per well) and cultured for an additional 2 (BGC823CDDP and SGC7901CDDP cells) or 3 weeks (BGC823 and SGC7901 cells). For scoring the colony-forming units, we fixed cells in 1 ml of methanol for 10 min and then stained the cells with crystal violet for 15 min.

**Apoptosis assay**

Cell apoptosis was detected using a PI/Annexin V-FITC Apoptosis Detection Kit (BD Pharmingen, 556,547) according to the manufacturer’s instructions. Briefly, after GC cells were treated with CDDP at the indicated concentrations for 48 h in 6-well plates, they were harvested and resuspended in 300 ml of binding buffer. Next, 5 μl of Annexin V-FITC and 5 μl of PI were added to the suspensions, and the cells were incubated in the dark at 4 °C for 15 min. The samples were subsequently analyzed with a flow cytometer (Gallios, Beckman, USA).

**Actinomycin D assay**

The Actinomycin D assay was performed as previously described [16]. SGC7901CDDP and BGC823CDDP cells were seeded in 5 wells in 24-well plates (5 × 10^4 cells per well). Twenty-four hours later, the cells were exposed to Actinomycin D (2 μg/ml, Abcam, ab141058) for 0 h, 6 h, 12 h, 18 h and 24 h. The cells were then harvested, and the relative RNA levels of circAKT3 and AKT3 mRNA were analyzed by RT-qPCR and normalized to the values measured in the group in the 0 h group (mock treatment).

**Immunofluorescence staining**

Cells seeded onto coated cover slips growth for 24 h, then treated with CDDP, and harvested the cells at 0, 2, and 8 h. The cells were fixed with 4% paraformaldehyde at room temperature for 15 min and then permeabilized with PBS containing 0.25% Triton X-100 for 10 min. Next, the cells were blocked with 1% BSA for 20 min before incubation with primary antibodies at room temperature for 2 h. After the cells were washed with PBS, they were incubated with appropriate secondary antibodies (FITC-conjugated goat anti-rabbit, Molecular Probes, USA) at room temperature for 2 h. Following a final wash with PBS, cells were mounted with antifading mounting medium containing DAPI. The images were
Fig. 4 (See legend on next page.)
Captured with a Leica DM13000B (Germany) fluorescence microscope.

Transduction with lentivirus
SGC7901CDDP cells stably expressing circAKT3 siRNA (si-circ-1) and its negative control siRNA (si-NC) were generated by infection with lentiviruses as previously described [20]. Transfection was carried out according to the manufacturer's instructions. The lentiviral expressing vectors were purchased from HanBio Co. Ltd. (Shanghai, China).

Nude mouse xenograft model
Six-week-old female BALB/c nude mice were purchased from the Laboratory Animal Center of Nanjing Medical University and maintained under pathogen-free conditions. A total of $5 \times 10^6$ SGC7901CDDP cells infected with lentivirus containing si-circ-1 or si-NC (2 μl of $10^9$ viral genomes μl⁻¹, HanBio) in 100 μl of PBS were subcutaneously injected into different sides of the groin of each mouse. One week after infection, we intraperitoneally injected mice with cisplatin (5 mg/kg) in PBS or PBS alone three times per week. The xenograft tumors were harvested after 5 weeks. The entire experimental protocol was conducted in accordance with the guidelines of the local institutional animal care and use committee.

Immunohistochemical staining (IHC)
Xenografts and GC tissues exposed to the indicated concentrations of CDDP were prepared for IHC as previously described [21]. Sections were identified by IHC Imager (DM4000B, LEIKA, Germany), and target protein expression levels were evaluated by the proportions and intensities of positive cells detected within 5 fields of view on every slide (400-fold magnification). Proportion scores were assigned as follows: $< 10\% = 0$, $10–25\% = 1$, $26–50\% = 2$, $51–75\% = 3$, and $> 75\% = 4$. Intensity scores were assigned as follows: $0 =$ no staining, $1 =$ weak, $2 =$ moderate, $3 =$ strong and $4 =$ significantly strong.

Statistical analysis
All experiments were performed in triplicate. Data were analyzed with SPSS 19.0 software (IBM, USA) and presented as the mean ± SEM. The statistical significance of the results was calculated using an unpaired Student’s t-test. DFS analysis was performed using the Kaplan-Meier method and log-rank test. Clinicopathological features were analyzed by a χ² test. A Cox proportional hazards regression model was used to identify independent prognostic factors associated with DFS. Linear correlation analyzes were performed to determine correlations between circAKT3, miR-198 and PIK3R1 expression levels. A P value<0.05 was defined as statistically significant.

Results
Ectopic circAKT3 expression levels are observed in CDDP-resistant GC cells and tissues and are correlated with poor prognosis in GC patients receiving CDDP therapy
To characterize circular RNA transcripts, we conducted RNA-Seq analysis of CDDP-resistant SGC7901 and BGC823 cells (i.e., SGC7901CDDP and BGC823CDDP) and their corresponding parental strains (i.e., SGC7901 and BGC823), which are sensitive to CDDP. The sequencing statistics are not shown. The analysis indicated that a series of circRNAs were differentially expressed in CDDP-resistant GC cells compared with the sensitive parental GC cells. We then chose the top 20 significantly upregulated circRNAs and verify their expression levels. Detailed information of 20 candidate circRNAs in Additional file 1: Table S8 (including location, genomic and spliced length). Using divergent primers to specifically target the circular junction as well as combined quantitative reverse transcription PCR (RT-qPCR) analysis and sequencing validation, we found that only 10 of these circRNAs had confirmed differences in expression and that circAKT3 was the most obviously upregulated circular RNA in CDDP-resistant patients of cohort 1 (Fig. 1a and Additional file 2: Figure S1b–c). CircAKT3 (hsa_circ_0000199) has been mapped to exons 8, 9, 10, and 11 of the AKT3 gene (555 bp) (Additional file 2: Figure S1d). Consistent with the RNA-Seq results, the expression of circAKT3 was obviously increased in CDDP-resistant GC cells (Fig. 1b). Subsequently, we
Fig. 5 (See legend on next page.)

Huang et al. Molecular Cancer (2019) 18:71
verified the head-to-tail splicing of the RT-PCR product of circAKT3 by Sanger sequencing (Fig. 1c). Meanwhile, to exclude possibilities such as genomic rearrangements or trans-splicing, several experiments were employed. First, we designed convergent primers to amplify AKT3 mRNA and divergent primers to amplify circAKT3. Using cDNA and genomic DNA (gDNA) from SGC7901CDDP and BGC823CDDP cell lines as templates, the circAKT3 amplification product was only observed in cDNA by divergent primers but not in gDNA (Fig. 1d). In addition, the fragment of the linear form of AKT3 was digested by RNase R, but circAKT3 remained after RNase R treatment (Fig. 1e). Then, the relative expression levels of circAKT3 were detected in the cytoplasm and nucleus of SGC7901CDDP and BGC823CDDP cells (Fig. 1f and Additional file 2: Figure S1f). The RT-qPCR results demonstrated that circAKT3 was enriched in the cytoplasm. Moreover, we used Actinomycin D to suppress transcription and measure the half-life of circAKT3 in SGC7901CDDP and BGC823CDDP cells; we found that circAKT3 was more stable than AKT3 mRNA (Fig. 1g and Additional file 2: Figure S1g) and divergent primers to amplify circAKT3. Using cDNA and genomic DNA (gDNA) from SGC7901CDDP and BGC823CDDP cells (Fig. 1h and Additional file 2: Figure S1e). The RT-qPCR results demonstrated that circAKT3 was enriched in the cytoplasm.

Next, we detected the expression level of circAKT3 in tissues of patients from cohort 2. Consistent with the RNA-Seq results, circAKT3 was significantly more highly expressed in the CDDP-resistant GC tissues than in the sensitive tissues (Fig. 2a). Compared with GC patients expressing low levels of circAKT3, GC patients receiving CDDP therapy and exhibiting upregulation of circAKT3 showed a significant association with decreased five-year DFS (Fig. 2b). To further verify that circAKT3 may be a therapeutic target for CDDP-resistant patients, we calculated the area under the receiver operating characteristic curve (AUC) using the expression levels of circAKT3. The area under the curve is 91% (Fig. 2c), suggesting that the expression level of circAKT3 is a good predictive biomarker of CDDP resistance for GC patients. Analysis of the clinicopathological characteristics in cohort 2 showed that circAKT3 expression was positively related to tumor size, histological grade, clinical stage, T classification and CDDP resistance (Table 1). A univariate analysis showed that DFS was obviously related to tumor size, histological grade, clinical stage, and circAKT3 expression level (Additional file 1: Table S9). Subsequently, multivariate analysis indicated that circAKT3 expression, along with tumor size and clinical stage, was an independent risk factor for DFS (Additional file 1: Table S9 and Fig. 2d).

circAKT3 facilitates CDDP resistance in vitro
First, we designed two siRNA oligonucleotides (si-circ-1 and si-circ-2) to target the unique back-splice junction of circAKT3 (Fig. 3a); si-circ-1 successfully knocked down circAKT3 expression but had no effect on the levels of endogenous linear AKT3 transcript in SGC7901CDDP and BGC823CDDP cells (Fig. 3b and Additional file 4: Figure S2a). Additionally, to further assess the role of circAKT3, circAKT3 was overexpressed in SGC7901 and BGC823 cells via transfection of pCD5-cir-AKT3 e8–11 (Fig. 4a). Importantly, elevated expression of circAKT3 had no effect on the levels of linear AKT3 mRNA, as confirmed by RT-qPCR (Fig. 4a). circAKT3 inhibition reduced the viability of SGC7901CDDP and BGC823CDDP cells (Fig. 3c and Additional file 4: Figure S2b). In addition, knockdown of circAKT3 significantly decreased the number of cell colonies (Fig. 3d and Additional file 4: Figure S2c) and promoted apoptosis (Fig. 3e and Additional file 4: Figure S2d). The phosphorylated histone family member X (γH2AX) forms discrete nuclear foci and acts as a platform to recruit additional factors and enhance the DNA repair pathway [22]. Meanwhile, circAKT3-knockdown cells showed significantly more γH2AX foci at the control cells at 2 h after CDDP treatment (Fig. 3g and Additional file 4: Figure S2e). circAKT3-knockdown cells had a higher percentage of active foci relative to that in control cells from 0 to 8 h after CDDP treatment (Fig. 3h and Additional file 4: Figure S2f). However, compared with the negative control, ectopic circAKT3 expression significantly increased cell viability and the number of cell colonies and inhibited apoptosis and the formation of γH2AX foci in SGC7901 and BGC823 cells (Fig. 4b-g and Additional file 5: Figure S3a-e). We used western blotting to investigate the underlying mechanism of these activities. In the presence of CDDP, knockdown of circAKT3 in SGC7901CDDP and BGC823CDDP cells increased cleaved caspase-3 protein levels, while the levels of the inactivated form of caspase-3 protein was decreased (Fig.
Fig. 6 (See legend on next page.)
In contrast, cleaved and inactivated caspase-3 protein levels were observed when circAKT3 was overexpressed (Fig. 4e). These data are consistent with a previous study reporting that CDDP-induced increases in Breast cancer type 1 susceptibility protein (BRCA1) expression leads to enhanced DNA damage repair (DDR) in breast cancer cells [23]. After CDDP treatment, knockdown of circAKT3 in SGC7901CDDP and BGC823CDDP cells increased γH2AX but decreased BRCA1 protein levels. circAKT3 overexpression also inhibited γH2AX and promoted BRCA1 protein levels compared with the levels in the controls (Figs. 3i and 4h).

**circAKT3 exerts its function by sponging miR-198**

To address whether circAKT3 could sponge miRNAs in GC cells, we selected 11 candidate miRNAs by overlapping the prediction results of the miRNA recognition elements in the circAKT3 sequence using miRanda, PITA, and RNAhybrid (Fig. 5a-b). Next, we investigated whether candidate miRNAs could directly bind circAKT3. A biotin-labeled circAKT3 probe was designed and verified to pull down circAKT3 in SGC7901CDDP and BGC823CDDP cell lines, and the pull-down efficiency was significantly enhanced in cells with stable circAKT3 overexpression (Fig. 5c-d). The miRNAs were extracted after pull-down, and the levels of the 11 candidate miRNAs were detected by RT-qPCR. As shown in Fig. 5e-f, in both SGC7901CDDP and BGC823CDDP cells, miR-198 was abundantly pulled down by circAKT3. Furthermore, using the RNAhybrid bioinformatics prediction tool, we calculated the secondary conformation of circAKT3 and miR-198 and found that there were 8 predicted binding domains (largest combined with a MFE > −20 kcal/mol) (Additional file 3: Dataset S2). Next, the results of the luciferase reporter assays showed that miR-198 expression significantly reduced the luciferase activity of the reporter containing the complete circAKT3 sequence appended to the 3′-UTR of luciferase (luc-wt) compared to that of the reporter containing circAKT3 with mutated miR-198 binding sites (luc-m1, m2 and m8) (Fig. 5g-h). Moreover, RNA FISH assays revealed that circAKT3 and miR-198 were colocalized in the cytoplasm (Fig. 5i).

**PIK3R1 is a direct target of miR-198**

A microarray assay was further performed with SGC7901CDDP, BGC823CDDP, SGC7901 and BGC823 cells to validate the results of the ceRNA analysis. We analyzed the top 20 upregulated genes according to four algorithms (miRanda, RNAhybrid, miRWalk and TargetScan) prediction, and miR-198 could target the 3′UTRs of PIK3R1, CHRM3, HIPK2 and MAFB (Additional file 3: Dataset S3). We performed luciferase reporter assays to determine whether miR-198 directly targets these 4 genes in 293 T cells (Fig. 6c and Additional file 6: Figure S4c and e). In 293 T, SGC7901CDDP and BGC823CDDP cells cotransfected with miR-198 mimic, reporter constructs containing wild-type miR-198 binding sites at the PIK3R1 3′UTR exhibited decreased luciferase activity relative to that of reported constructs with mutated binding sites (Fig. 6d and Additional file 6: Figure S4f and g). PIK3R1 protein (p85α, encoded by PIK3R1) is the regulatory subunit of PI3K. A functional study demonstrated that PIK3R1 was highly expressed in CDDP-resistant ovarian cancer cells, and downregulated PIK3R1 resensitized the abovementioned cells to platinum-based treatment, which reveals the promising involvement of p85α in secondary CDDP resistance [24]. Compared with parental CDDP-sensitive cells, CDDP-resistant cells showed obvious increases in the expression of PIK3R1 mRNA and protein levels (Fig. 6f and g). Furthermore, we found that miR-198 mimics significantly inhibited PIK3R1 mRNA and protein levels and that ectopic PIK3R1 expression abolished the influence caused by miR-198 overexpression (Fig. 6h and i). Subsequently, the data showed that overexpression of miR-198 inhibited cell viability and induced apoptosis in SGC7901CDDP and BGC823CDDP cells. However, cotransfection of PIK3R1 and miR-198 abrogated these effects (Fig. 6j and k and Additional file 6: Figure S4h-j and Additional file 7: Figure S5a-b).
Fig. 7 (See legend on next page.)
circAKT3 regulates PIK3R1 expression, activates the PI3K/AKT signaling pathway and ultimately facilitates CDDP resistance by targeting miR-198 in vitro

Cotransfection of si-circ-1 and anti-miR-198 could counteract the si-circ-1-induced downregulation of PIK3R1 in SGC7901CDDP cells (Fig. 7a). Notably, cotransfection of circAKT3 and miR-198 attenuated the expression of PIK3R1 compared to transfection of circAKT3 alone in SGC7901 cells (Fig. 7b). The CCK8 and flow cytometry analyses indicated that transfection with si-circ-1 inhibited cell viability and promoted apoptosis after CDDP treatment while cotransfection with si-circ-1 and anti-miR-198 significantly promoted cell viability and inhibited apoptosis compared with the controls (Fig. 7c and d, Additional file 7: Figure S5d). Furthermore, upregulation of circAKT3 led to enhanced cell viability, but this effect could be significantly abolished by ectopic expression of miR-198 (Additional file 8: Figure S6a). Additionally, overexpression of circAKT3 induced a reduction in apoptosis. However, cotransfection of circAKT3 and miR-198 mimics led to enhanced apoptosis (Additional file 8: Figure S6b). Notably, circAKT3 upregulation could inhibit γH2AX expression, as indicated by the reduced fluorescence of γH2AX, cotransfection of circAKT3 and miR-198 mimics led to abolish this effect (Additional file 8: Figure S6c and d). Transfection of si-circ-1 significantly reduced PIK3R1 expression and inhibited the expression of canonical PI3K/AKT signaling molecules, as shown by western blot, and downregulating of both circAKT3 and miR-198 abrogated these effects in SGC7901CDDP cells (Fig. 7e). Similar results are presented in Additional file 9: Figure S7a-f. Meanwhile, Transfection of circAKT3 significantly increased PIK3R1 expression and induced the expression of canonical PI3K/AKT signaling molecules, as shown by western blot, and concomitant overexpression of both circAKT3 and miR-198 abrogated these effects in SGC7901 cells (Fig. 7f). Transfection of si-PIK3R1 significantly inhibited PIK3R1 and levels of phosphorylated PI3K/AKT signaling molecules in SGC7901 cells with circAKT3 overexpression. We employed a specific p110α inhibitor, BKM20, and performed western blotting to determine whether deactivation of PI3K/AKT signaling can overcome the changes caused by circAKT3 overexpression. The results indicated that si-PIK3R1 and BKM20 significantly inhibited PIK3R1 and p110α levels, respectively as well as inhibited p-AKT, reduced BRCA1 levels, increased cleaved caspase-3 levels, and promoted γH2AX (Fig. 7g). These results suggest that circAKT3 functions by targeting miR-198 as a ceRNA to regulate PIK3R1 expression, activate the PI3K/AKT signaling cascade and facilitate CDDP resistance.

circAKT3 promotes CDDP resistance of GC cells in vivo

To investigate the potential clinical relevance of circAKT3 in vivo, we subcutaneously injected SGC7901CDDP cells with or without stable circAKT3 knockdown (Additional file 8: Figure S6e) into the dorsal flanks of female BALB/c nude mice and allowed the cells to proliferate for 5 weeks. Tumor xenograft data indicated that circAKT3 inhibition in CDDP-resistant cells can significantly decrease xenograft tumor growth and sensitize cells to CDDP treatment (Fig. 8a and b). IHC analysis of tumor xenograft samples further indicated that the protein levels of γH2AX and cleaved caspase-3 were notably increased, but BRCA1 was decreased upon circAKT3 inhibition (Fig. 8c). FISH showed the colocalization of circAKT3 and miR-198 in tissues from patients with CDDP-resistant or CDDP-sensitive GC (Fig. 8d). The FISH score data showed that the expression of circAKT3 was significantly higher in CDDP-resistant GC tissues than CDDP-sensitive GC tissues; however, miR-198 expression showed the opposite result (Fig. 8d). Similarly, IHC scores and western blot analyses indicated that PIK3R1 protein expression was obviously increased in CDDP-resistant GC tissues compared to CDDP-sensitive GC tissues (Fig. 8e and Additional file 10: Figure S8a and b). Furthermore, correlations were identified between circAKT3 and miR-198 expression levels and PIK3R1 protein levels in these 44 GC tissue samples (Fig. 8f). Based on these data, we conclude that circAKT3...
Fig. 8 (See legend on next page.)
increases the tolerance of GC cells to CDDP by targeting PIK3R1 through miR-198.

**Discussion**

CDDP treatment is one of the most predominant chemotherapeutic strategies for patients with GC [25]. In this study, using RNA-Seq analysis, we determined that circRNA expression is associated with CDDP resistance in GC. We found a novel circular RNA termed circAKT3 that was upregulated in tissue samples from patients with CDDP-resistant GC and in CDDP-resistant cell lines and was correlated with five-year DFS. Moreover, circAKT3 was expressed at higher levels than other candidate circRNAs in CDDP-resistant GC patients, which meant that it may play a more important role than other circRNAs in GC.

DNA is the recognized target for CDDP cytotoxicity in cancer therapy. The resultant biological process in response to CDDP and other DNA-damaging therapies is the activation of apoptosis and the destruction of malignant cells. The most favorable evidence is the hypersensitivity of both eukaryotic and prokaryotic cells deficient in DNA repair to CDDP [26]. An enhanced DNA repair mechanism can induce the survival of damaged or mutated tumor cells, resulting in resistance and subsequent tumor recurrence [27]. BRCA1, a tumor-suppressor gene, is widely involved in cellular metabolism [28], transcriptional regulation [29, 30], and epigenetic modification [31]. A growing body of evidence revealed that BRCA1 has a great effect on the repair of CDDP-resistant GC patients [32–34]. Alternative BRCA1 expression can regulate the mitochondrial fission program, which could modulate CDDP sensitivity [32]. Some microRNAs contribute to DNA repair and CDDP sensitivity through BRCA1 deregulation, including miR-9 [35] and miR-638 [36]. A previous study demonstrated that BRCA1 mRNA levels were negatively associated with CDDP sensitivity in GC [37]. Currently, there is a lack of research on circRNAs that regulate the BRCA1 gene in tumor cells, including GC. The underlying mechanisms require further exploration.

PIK3R1 encodes the regulatory subunit of PI3K (p85α). Some studies have reported that p85α positively regulates PI3K signaling in CDDP resistance. Because the PI3K pathway is a critical player in tumorigenesis and the ubiquitously hyperactivated signaling pathway in neoplasms, its inhibition both pharmacologically and genetically is considered to be the most promising strategy for targeted cancer treatment [38]. The PI3K pathway has been revealed as a mediator of platinum resistance [39, 40] For instance, AKT activation mediated resistance to caspase-independent CDDP-induced apoptosis through inhibiting the apoptosis-inducing factor-associated pathway [40]. One study reported that PI3K/AKT activation induced the upregulation of BRCA1 in tamoxifen-resistant breast cancer cells and resensitized them to CDDP treatment [23]. Nevertheless, the underlying mechanism of how PIK3R1 mediates resistance to chemotherapy and whether this involves canonical PI3K signaling and downstream BRCA1 activity remains to be investigated in GC.

Based on the abovementioned studies, we conducted a series of experiments and demonstrated that circAKT3 reduced CDDP-induced activation of caspase-3 and apoptosis, leading to enhanced DDR and resistance to CDDP chemotherapy. Mechanistically, circAKT3 functions as a ceRNA by sponging miR-198 to abolish the suppressive effect of this miRNA on its target gene PIK3R1, which activated the PI3K/AKT signaling pathway in GC cells. The study showed that PI3K/AKT pathway activation contributes to upregulation of the DNA repair molecule BRCA1 and leads to resistance to CDDP-based DNA-damaging chemotherapy [23]. In the current study, circAKT3 influenced DDR in GC cells, implying that circAKT3 might enhance CDDP resistance through the PI3K/AKT pathway and DDR mechanisms in GC cells. However, there are some drawbacks in this study, and we have not yet identified the specific mechanism by which BRCA1 regulates DDR in GC. At the same time, the reasons for circAKT3 shear formation and the upstream regulatory mechanism were not discussed. For the in vivo experiments, we did not use animal models of GC in situ, nor did we fully simulate the process of drug resistance. These approaches should be further pursued in subsequent studies.
Conclusions
In conclusion, we show that circAKT3 is upregulated in human GC and that it can efficiently sponge miR-198 to restore PIK3R1 expression. We also demonstrate that downregulation of circAKT3 can effectively promote CDDP sensitivity in GC cells by targeting the miR-198/PIK3R1 axis. Our results provide novel evidence that cir-cRNAs function as “microRNA sponges” and highlight a promising therapeutic target for the CDDP resistance of GC patients.

Additional files

Additional file 1: Table S1. Detailed information of cohort 1 and 2 is listed. Table S2. Primers and RNA sequences used in this study. Table S3. siRNA sequences used in this study. Table S4. miRNA mimics, and inhibitors sequences used in this study. Table S5. Dextranoyl probes sequences used in this study. Table S6. Fish probes sequences used in this study. Table S7. Detailed information of antibody used in this study. Table S8. Detailed information of cohort 1 and 2 is presented. Table S9. Additional Dataset (2) circAKT3.

Additional file 2: Figure S1. a SGC7901CDDP/SGC7901 and BGC823CDDP/BGC823 cell viability in response to different concentrations of cisplatin. b RT-qPCR products with divergent primers showing a single, distinct product of the expected size. c Melting curves of RT-qPCR product of verified circRNAs, indicating the specificity of RT-qPCR products with no primer dimers or nonspecific amplified products. d Schematic illustrating that circAKT3 (hsa_circ_0001919) is derived from exons 6, 9, 10, and 11 of the AKT3 gene (555 bp). e Levels of small nucleolar RNA (U6, as a positive control for the nuclear fraction), GAPDH (positive control for the cytoplasmic fraction), AKT3 mRNA and circRNAs from nuclear and cytoplasmic fractions of BGC823CDDP cells. f RNA stability of the circular and linear transcripts of AKT3 and 18S rRNA in BGC823CDDP cells. The results are presented as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. (TIF 2497 kb)

Additional file 3: Additional Dataset (1) miRNA target prediction of circAKT3. Additional Dataset (2) Eight miR-198 binding sites mutation of circAKT3. Additional Dataset (3) miRNA target prediction of miR-198. (ZIP 1800 kb)

Additional file 4: Figure S2. a RT-qPCR results for the circular and linear transcripts of AKT3 in BGC823CDDP cells treated with or without siRNA (NC, negative control; si-NC, control oligonucleotides with scramble sequence; si-circ-1 and si-circ-2, oligonucleotides targeting the back-splice junction). b Relative cell viability of NC BGC823CDDP cells and BGC823CDDP cells transfected with si-NC or si-circ-1 in the absence (Vehicle) or presence of CDDP (15 μM) at 48 h. c Colony-forming ability of the NC BGC823CDDP cells and si-NC- or si-circ-1-transfected BGC823CDDP cells in the absence (Vehicle) or presence of CDDP (15 μM) for 48 h. d The apoptosis rates of NC BGC823CDDP cells and BGC823CDDP cells transfected with si-NC or si-circ-1 at 48 h after CDDP treatment at the indicated concentrations for 48 h. e Colony-forming ability of the NC BGC823CDDP cells and si-NC- or si-circ-1-transfected BGC823CDDP cells in the absence (Vehicle) or presence of CDDP (15 μM) for 48 h. f The apoptosis rates of NC BGC823CDDP cells and BGC823CDDP cells transfected with si-NC or si-circ-1 at 2 h after CDDP treatment (15 μM). Scale bars: 10 μm. The percentage of cells containing >10 yH2AX foci in NC BGC823CDDP cells and BGC823CDDP cells transfected with si-NC or si-circ-1 at 0 to 8 h after CDDP treatment (15 μM) removal. The results are presented as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. (TIF 5287 kb)

Additional file 5: Figure S3. a Relative cell viability of circAKT3- or vector-transfected BGC823 cells with CDDP treatment at the indicated concentrations for 48 h. b Colony-forming ability of BGC823 cells transfected with circAKT3 or vector in the absence (Vehicle) or presence of CDDP (1.5 μM) for 48 h. c The apoptosis rates of BGC823 cells transfected with circAKT3 or vector upon CDDP (1.5 μM) for 48 h by flow cytometry. d Immunofluorescence staining of yH2AX foci in BGC823 cells transfected with circAKT3 or vector at 2 h after CDDP treatment (1.5 μM). Scale bars: 10 μm. e Percentage of cells containing >10 yH2AX foci in BGC823 cells transfected with circAKT3 or vector at 0 to 8 h after CDDP treatment (1.5 μM) removal. The results are presented as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. (TIF 3594 kb)

Additional file 6: Figure S4. a Predicted secondary structure of circAKT3 using the Vienna RNA package. b The expression of miR-198 was analyzed using RT-qPCR in tissues of cohort 1. c, d, e The relative luciferase activities were analyzed in 293T cells cotransfected with miR-198 mimics or miR-NC and luciferase reporter vectors containing the WT or Mut 3’UTR of CHRM3 (C), HIPK2 (D), and MAFB (E). f, g The relative luciferase activities were analyzed in SGC7901CDDP and BGC823CDDP cells cotransfected with miR-198 mimics or miR-NC and luciferase reporter vectors PIK3R1 3’UTR (WT) or PIK3R1 3’UTR (Mut). h, i The expression levels of PIK3R1 (h) and miR-198 (i) in SGC7901CDDP and BGC823CDDP cells after transfection of PIK3R1 plasmids or miR-198 mimics were detected by RT-qPCR. The IC50 of miR-198 was analyzed by the CCK8 assay. BGC823CDDP cells were transfected with miR-198 mimic alone or cotransfected with the indicated vectors upon CDDP exposure (15 μM) for 48 h. The results are presented as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. (TIF 1650 kb)

Additional file 7: Figure S5. a Apoptotic flow cytometry. SGC7901CDDP cells were cotransfected with PIK3R1 mimic or inhibitor vectors upon CDDP exposure (6 μM) for 48 h. b The apoptosis rate was analyzed by flow cytometry. BGC823CDDP cells were transfected with mi-R198 mimic alone or cotransfected with the indicated vectors upon CDDP exposure (15 μM) for 48 h. c The expression levels of miR-198 in SGC7901CDDP and BGC823CDDP cells after transfection of anti-miR-198 were detected by RT-qPCR. d Apoptotic flow cytometry. SGC7901CDDP cells transfected with indicated vectors alone or cotransfected the inhibitors upon CDDP exposure (6 μM) for 48 h. The results are presented as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. (TIF 2160 kb)

Additional file 8: Figure S6. a The IC50 was analyzed by CCK8 assay. SGC7901 cells were transfected with inhibitor alone or cotransfected with the indicated vectors upon CDDP exposure (1.5 μM) for 48 h. b The apoptosis rate was analyzed by flow cytometry. SGC7901 cells were transfected with inhibitor alone or cotransfected with the indicated vectors upon CDDP exposure (1.5 μM) for 48 h. c The expression levels of miR-198 in SGC7901CDDP and BGC823CDDP cells after transfection of PIK3R1 plasmids or miR-198 mimics were detected by RT-qPCR. The IC50 of miR-198 was analyzed by the CCK8 assay. BGC823CDDP cells were transfected with miR-198 mimic alone or cotransfected with the indicated vectors upon CDDP exposure (6 μM) for 48 h. The results are presented as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. (TIF 2595 kb)

Additional file 9: Figure S7. a The expression levels of PIK3R1 were analyzed using RT-qPCR. SGC7901CDDP cells were cotransfected with inhibitors alone or the indicated vectors. b The IC50 of circAKT3 was analyzed by the CCK8 assay. SGC7901CDDP cells were transfected with inhibitor alone or cotransfected with the indicated vectors upon CDDP exposure (6 μM) for 48 h. c The apoptosis rates of SGC7901CDDP cells transfected with inhibitor alone or cotransfected with the indicated vectors upon CDDP exposure (6 μM) for 48 h. d Immunofluorescence staining of yH2AX foci in SGC7901 cells transfected with inhibitor alone or cotransfected with the indicated vectors at 2 h after CDDP treatment (1.5 μM). Scale bars =10 μm. d Percentage of cells containing >10 yH2AX foci in SGC7901 cells transfected with inhibitor alone or cotransfected with the indicated vectors at 0 to 8 after CDDP treatment (1.5 μM) removal. e SGC7901CDDP cells stably expressing circAKT3 siRNA (si-circ-1) and its negative control siRNA (si-NC) were generated by infection with lentiviruses, the expression levels of circAKT3 were detected by RT-qPCR. The results are presented as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. (TIF 2160 kb)
were determined using western blotting in SGC7901/DDP cells transfected with inhibitor alone or cotransfected with the indicated vectors after DDP treatment (6 μM). The results are presented as the mean ± SEM. **P<0.01, ***P<0.001. (TIF 2588 kb)

Additional file 10: Figure S8. a The expression of PIK3R1 were analyzed using western blot in tissue of cohort 1. b The expression of PIK3R1 were further determined in tissues of 14 CDPP-resistant and 30 CDPP-sensitive patients (Relative to GAPDH). (TIF 604 kb)

Abbreviations

AUC: Area under the receiver operating characteristic curve; BRCAt1: Breast cancer type 1 susceptibility protein; CK8: Cell Counting Kit-8; CDDP: Cisplatin; cellRNAs: Competitive endogenous RNAs; circRNAs: Circular RNAs; DDR: DNA damage repair; DFS: Disease-free survival; FBS: Fetal bovine serum; FISH: Fluorescence in situ hybridization; FL: Firefly luciferase; GC: Gastric cancer; gDNA: Genomic DNA; IHC: Immunohistochemical staining; MFE: Minimum free energy; miRNAs: MicroRNAs; mtDNA: Mitochondrial DNA; ncRNAs: Noncoding RNAs; RNA-Seq: RNA sequencing; RT-PCR: Quantitative real-time PCR; RT-qPCR: Quantitative reverse transcription PCR; yH2AX: Phosphorylated histone family member X

Acknowledgments

Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University.

Funding

This work was supported by the National Natural Science Foundation of China (81572362); the National Natural Science Foundation Project of International Cooperation (NSFC-NIH, 81361120398); the Primary Research & Development Plan of Jiangsu Province (BE2016786); the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX10231801); 333 Project of Jiangsu Province (XYY2015474); Jiangsu Key Medical Discipline (General Surgery)(2016005); University Natural Science Research Project of Anhui Province(KJ2018A0247); Wannan Medical College Cultivation Fund of the Key Scientific Project(WQK2017ZF10).

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its Additional files.

Authors' contributions

ZKX, ZL and WZW conceived of the study and conducted the experiments. ZKX, ZL and SYH collected clinical samples. XXH, ALZ, QL, GLS and QL analyzed the data. XXH, BWL, LW, ZPX and XZ performed the experiments. XXH, XZ and ZKX conceived of the study and XXH carried out its design. ZYH, QZ, BWL, LW, ZPX and XZ performed the experiments. XXH, ZKX, ZL and WZW conceived of the study and XXH carried out its design.

Ethics approval and consent to participate

The present study was approved by the Hospital's Protection of Human Subjects Committee.

Consent for publication

We have received consents from individual patients who have participated in this study. The consent forms will be provided upon request.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu province, China. 2Department of Gastrointestinal Surgery, The First Affiliated Yiyishan Hospital of Wannan Medical College, Wuhu, Anhui, China. 3Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Received: 21 November 2018 Accepted: 21 February 2019

Published online: 30 March 2019

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E539–86.
3. Zhao TT, Xu H, Xu HM, Wang ZN, Xu YY, Song YX, Yin SC, Liu YX, Miao ZF. The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials. Gastric Cancer. 2018;21(3):361–71.
4. Koizumi W, Narahara H, Haro T, Takagane A, Akiy G, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takeyama W, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(5):215–21.
5. Longley DB, Harkin DP, Johnston PG. S-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8.
6. Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol. 2015;33(16):1760–9.
7. Yang Z, Schumaker LM, Ergin MI, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res. 2006;12(19):5817–25.
8. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.
9. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.
10. Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, et al. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 2008;122(2):433–43.
11. Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN and PI3KCA mRNAs amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005;97(1):26–34.
12. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–79.
13. Kulcheski FR, Christoff AP, Margis R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J Biotechnol. 2016;238:42–51.
14. Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnyaya I, et al. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol. 2016;34(33):4000–7.
15. Li B, Wang W, Li Z, Chen Z, Zhi X, Xu J, Li Q, Wang L, Huang X, Wang L, et al. MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett. 2017;410:212–7.
16. Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, Luo Y, Lyu D, Li Y, Shi G, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016;7:1215.
17. Wang K, Long B, Liu F, Wang JX, Liu CY, Zhao B, Zhou LY, Sun T, Wang M, Yu T, et al. A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. Eur J Heart. 2016;37(33):2602–11.
18. Hsiao KY, Lin YC, Gupta SK, Chang N, Yen L, Sun HS, Tsai SJ. Noncoding effects of circular RNA CCCDC66 promote Colon Cancer growth and metastasis. Cancer Res. 2017;77(9):2339–50.
19. Han D, Li J, Wang H, Su X, Hou J, Gu Y, Qian C, Lin Y, Liu X, Huang M, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2016;64(1):115–64.
20. Huang R, Zhang Y, Han B, Bai Y, Zhou R, Gan G, Chao J, Hu G, Yao H. Circular RNA HIPK2 regulates astrocyte activation via cooperation of autophagy and ER stress by targeting MIR124-2HG. Autophagy. 2017;13(10):1722–41.
21. Lu Y, Xiao L, Liu Y, Wang H, Li H, Zhou Q, Pan J, Lei B, Huang A, Qi S. MIR517C inhibits autophagy and the epithelial-to-mesenchymal (−like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation. Autophagy. 2015;11(12):2213–32.

22. Kinner A, Wu W, Staudt C, Ilakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008;36(17):5678–94.

23. Zhu Y, Liu Y, Zhang C, Chu J, Wu Y, Li Y, Liu J, Li Q, Li S, Shi Q, et al. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARDA1 and BRCA1. Nat Commun. 2018;9(1):1595.

24. Cheung LW, Mills GB. Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. Pharmacogenomics. 2016;17(3):297–307.

25. Mo D, Fang H, Niu K, Liu J, Wu M, Li S, Zhu T, Aleksandarany MA, Arora A, Lobo DN, et al. Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT-YB1-MDR1 signaling pathway. Cancer Res. 2016;76(10):3057–66.

26. Fraval HN, Rawlings CJ, Roberts JJ. Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res. 1978;51(1):121–32.

27. Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yi-Harja O, Nykter M, et al. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci U S A. 2015;112(11):3421–6.

28. Li D, Chen NN, Cao JM, Sun WP, Zhou YM, Li CY, Wang XX, BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer. Cell Cycle. 2014;13(16):2564–71.

29. Dacheux E, Vincent A, Nazaret N, Combet C, Wierinckx A, Mazoyer S, Diaz JJ, Lacquer J, Venezia ND. BRCA1-dependent translational regulation in breast cancer cells. PIlos One. 2013;8(6):e67313.

30. Li D, Bi FF, Chen NN, Cao JM, Sun WP, Zhou YM, Cao C, Li CY, Yang Q. Epigenetic repression of phosphatidylethanolamine N-methyltransferase (PEMT) in BRCA1-mutated breast cancer. Oncotarget. 2014;5(5):1315–25.

31. Li D, Bi FF, Cao JM, Cao C, Liu B, Yang Q. Regulation of DNA methyltransferase 1 transcription in BRCA1-mutated breast cancer: a novel crosstalk between EZF1 motif hypermethylation and loss of histone H3 lysine 9 acetylation. Mol Cancer. 2014;13:26.

32. Fan S, Liu B, Sun L, Xu XB, Lin Z, Chen W, Chen W, Tang Q, Wang Y, Su Y, et al. Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MEF axis. Oncotarget. 2015;6:14885–904.

33. Paul BT, Blanchard Z, Ridgway M, ESHamy WM. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin. Oncogene. 2015;34(23):3036–52.

34. Shin DH, Choi YJ, Park JW. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin. Cancer Res. 2014;74(1):298–308.

35. Sun C, Li N, Yang Z, Zhou H, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, et al. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst. 2013;105(22):1750–8.

36. Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, Teal CB, Man YG, Brem RF, Fu SW. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res. 2014;16(5):435.

37. Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008;8:97.

38. Hennessy BT, Smith DL, Ram PT, ElShamy WM. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin. Oncogene. 2015;34(23):3036–52.

39. Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, Brosens JJ, Lam EW. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 2008;7(3):670–8.

40. Yang X, Fraser M, Abedini MR, Bai T, Tung BK. Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Br J Cancer. 2008;98(4):803–8.